Zynex, Inc. (NASDAQ:ZYXI) CFO Daniel J. Moorhead Sells 10,000 Shares

Zynex, Inc. (NASDAQ:ZYXI) CFO Daniel J. Moorhead sold 10,000 shares of the firm’s stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $8.08, for a total transaction of $80,800.00. Following the sale, the chief financial officer now directly owns 35,190 shares in the company, valued at approximately $284,335.20. The trade was a 22.13 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Zynex Stock Down 0.9 %

Shares of ZYXI stock opened at $7.94 on Friday. The stock has a market cap of $252.89 million, a P/E ratio of 52.93 and a beta of 0.49. The company’s fifty day simple moving average is $8.25 and its two-hundred day simple moving average is $8.61. The company has a quick ratio of 3.15, a current ratio of 3.94 and a debt-to-equity ratio of 1.66. Zynex, Inc. has a 52 week low of $7.15 and a 52 week high of $13.77.

Zynex (NASDAQ:ZYXI) last released its quarterly earnings data on Thursday, October 24th. The company reported $0.07 EPS for the quarter, beating the consensus estimate of $0.06 by $0.01. Zynex had a net margin of 2.49% and a return on equity of 13.05%. The business had revenue of $49.97 million during the quarter, compared to analyst estimates of $50.83 million. During the same quarter last year, the business earned $0.10 earnings per share. Zynex’s quarterly revenue was up .1% compared to the same quarter last year. Analysts predict that Zynex, Inc. will post 0.2 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have weighed in on ZYXI shares. HC Wainwright boosted their target price on shares of Zynex from $16.00 to $17.00 and gave the company a “buy” rating in a research note on Friday, October 25th. Royal Bank of Canada reduced their target price on shares of Zynex from $12.00 to $11.00 and set an “outperform” rating for the company in a report on Tuesday, October 8th.

Institutional Investors Weigh In On Zynex

Several hedge funds have recently made changes to their positions in the company. Gladius Capital Management LP lifted its stake in shares of Zynex by 53.4% during the 3rd quarter. Gladius Capital Management LP now owns 5,002 shares of the company’s stock worth $41,000 after purchasing an additional 1,742 shares during the last quarter. Investment Partners Asset Management Inc. purchased a new position in Zynex during the 3rd quarter worth $96,000. Hsbc Holdings PLC acquired a new position in Zynex during the 2nd quarter valued at about $113,000. Quest Partners LLC raised its stake in Zynex by 646.7% in the second quarter. Quest Partners LLC now owns 12,926 shares of the company’s stock valued at $120,000 after buying an additional 11,195 shares during the last quarter. Finally, Principal Financial Group Inc. boosted its holdings in Zynex by 10.4% in the second quarter. Principal Financial Group Inc. now owns 19,525 shares of the company’s stock worth $182,000 after acquiring an additional 1,846 shares in the last quarter. 29.68% of the stock is currently owned by hedge funds and other institutional investors.

About Zynex

Zynex, Inc, together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device.